Platform for Oligonucleotide Drug Production (Nucleic Acid Drugs for the Treatment of Pulmonary Fibrosis)
Pulmonary fibrosis refers to the loss of control of fibroblasts in the repair process of the lung after damage, which makes the lung tissue harden and gradually lose its ability, is called Idiopathic Pulmonary Fibrosis (IPF). With the backing of the Department of Technology, Ministry of Economic Affairs, DCB has made significant investments in establishing the first domestic platform for the research and production of oligonucleotide drugs. This platform has successfully developed nucleic acid drug synthesis, purification, and analysis technologies, enabling the production of pharmaceutical-grade nucleic acid drugs weighing 100mg with a purity exceeding 90%. Collaborating with Dr. Yang, Kai-Chien from National Taiwan University College of Medicine, DCB has made groundbreaking advancements in the development of a short-chain nucleic acid drug for the treatment of pulmonary fibrosis. Extensive mouse trials have substantiated its efficacy in effectively impeding the progression of the disease. Going forward, the research will continue and progress to clinical trials. The primary objective of this research platform is to advance technology and elevate Taiwan's research capabilities in the field of oligonucleotide drug development, look forward to bringing hope to patients.
With over 400 dedicated researchers and state-of-the-art facilities , the Development Center for Biotechnology (DCB) specializes in developing biologics and small molecule drugs , botanical drugs , as well as technologies required for preclinical testing. Our expertise arises from the integration of a number of diverse disciplines , including biology , chemistry , protein purification and engineering , as well as analytical and quality assurance. Established in 1984 by Taiwan's Ministry of Economic Affairs (MOEA) , Department of Industrial Technology (DoIT) , DCB was initially tasked with establishing the biotechnology industry in Taiwan. Through strategic global alliances and technology transfer agreements , DCB has successfully fostered the development of a complete biotech infrastructure and value chain , as well as a diverse array of applications for use by the private sector. As a result , DCB has become one of Taiwan's most important research institutes. DCB's mission is to facilitate the ongoing growth and development Taiwan's biotechnology industry. To this end , we strive to act as the industry's partner , coordinating resources among government , academia and private companies. DCB remains a key force in building and upgrading Taiwan's biomedical infrastructure, developing key technologies , and growing Taiwan's professional workforce. Our ultimate aim is to improve the quality of life for the people of Taiwan and the world. To this end , DCB fosters international partnerships and collaborations with research institutes and global biopharmaceuticals throughout Asia and the world.
Name:
Phone:
Address:No.107, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei City 11571, Taiwan, R.O.C.
Ultrahigh-Sensitive Detection Platform Powered by Semiconductor-based Biosensor for the evaluation of Treatment on Acute Myeloid Leukemia
Development of novel cannabinoid CB1receptor antagonists with high oral absorption and no central adverse effects for the treatment of cardiovascular diseases
Novel Autopilot Jet-Based Electrospinning for Fabricating Functional 3D Scaffolds for Tissue Engineering and Regenerative Medicine Applications
Smart Chitosan Hydrogel with Asynchronous Drug Release for the Treatment of intracerebral hemorrhage stroke
Technology maturity:Trial production
Exhibiting purpose:Technology transactions、Patent transactions、Product promotion、Display of scientific results
Trading preferences:Exclusive license/assignment、Technical license/cooperation
Coming soon!